Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

722
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
722

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune aging biomarkers for clinical trials.

Nature medicine·2026
Same author

Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency.

ERJ open research·2026
Same author

Reply to: "On the Distinction Between Prognostic and Predictive Inference in Multicancer Early Detection" and "Interpretation of Survival Outcomes in Multicancer Early Detection Testing Requires Caution".

JCO precision oncology·2026
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

Mutation-dependent responses to sleep and exercise in clonal haematopoiesis.

Nature·2026
Same author

Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same journal

Patient value over patent value: the mandate for open-source oncology.

Nature reviews. Clinical oncology·2026
Same journal

Cancer burden and control in China: landscape, trends and challenges.

Nature reviews. Clinical oncology·2026
Same journal

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Nature reviews. Clinical oncology·2026
Same journal

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer.

Nature reviews. Clinical oncology·2026
Same journal

Teclistamab monotherapy improves survival in RRMM.

Nature reviews. Clinical oncology·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Innovative approaches for lung cancer screening and interception.

Jianjun Zhang1,2, Matthew D Park3, Tej Pandya4,5,6

  • 1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jzhang20@mdanderson.org.

Nature Reviews. Clinical Oncology
|February 23, 2026
PubMed
Summary
This summary is machine-generated.

Lung cancer screening needs improvement. New biomarkers and precancer interception strategies are crucial for early detection and prevention, especially for those not meeting current low-dose CT scan guidelines.

More Related Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.3K
Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer
07:53

Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer

Published on: October 13, 2023

2.2K

Related Experiment Videos

Last Updated: May 3, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.3K
Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer
07:53

Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer

Published on: October 13, 2023

2.2K

Area of Science:

  • Oncology
  • Pulmonology
  • Radiology

Background:

  • Lung cancer is a leading cause of cancer death globally, often diagnosed late.
  • Low-dose computed tomography (LDCT) screening reduces mortality but has low uptake and misses many cancers.
  • Current LDCT guidelines exclude nearly half of lung cancer cases and have limitations like false positives and high costs.

Purpose of the Study:

  • To review the current status of lung cancer screening.
  • To discuss disparities and infrastructure for screening implementation.
  • To explore future directions in biomarkers and precancer interception.

Main Methods:

  • Literature review of lung cancer screening, biomarkers, and precancer interception strategies.
  • Analysis of current LDCT screening guidelines and limitations.
  • Synthesis of emerging research in radiomic features and liquid biopsy.

Main Results:

  • LDCT screening is effective but underutilized and has limitations.
  • Novel biomarkers (radiomics, liquid biopsy) show promise for risk prediction.
  • Pulmonary nodule detection necessitates strategies for precancer interception.

Conclusions:

  • Improving lung cancer screening requires addressing uptake barriers and guideline limitations.
  • Development of advanced biomarkers and precancer interception therapies is essential.
  • Transformative changes in prevention and early intervention are needed for lung cancer.